Bernd Kasper, MD, PhD, provides an overview of the phase 3 DeFi trial of nirogacestat for the treatment of patients with progressing desmoid tumors.
Bernd Kasper, MD, PhD
Bernd Kasper, MD, PhD, is a professor at Universitätsmedizin Mannheim, Mannheim.
Articles by Bernd Kasper, MD, PhD
Bernd Kasper, MD, PhD, discusses the key efficacy results from the updated analysis of the phase 3 DeFi trial of nirogacestat in desmoid tumors.